BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
A. G. G. TURPIE, W. D. FISHER, K. A. BAUER, L. M. KWONG, M. W. IRWIN, P. KÄLEBO, F. MISSELWITZ, M. GENT, FOR THE ODIXa-KNEE STUDY GROUPVolume:
3
Year:
2005
Language:
english
Pages:
8
DOI:
10.1111/j.1538-7836.2005.01602.x
File:
PDF, 233 KB
english, 2005